口服雄黄-青黛配方加维甲酸治疗急性早幼粒细胞白血病。
Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia.
作者信息
Lou Yinjun, Ma Yafang, Jin Jie, Zhu Honghu
机构信息
Department of Hematology, Leukemia Center, The First Affiliated Hospital of Zhejiang University, College of Medicine, Key Laboratory of Hematopoietic Malignancies in Zhejiang Province, Hangzhou, China.
出版信息
Front Oncol. 2021 Feb 5;10:597601. doi: 10.3389/fonc.2020.597601. eCollection 2020.
Abstract
Treatment paradigm of acute promyelocytic leukemia (APL) is by no mean the most remarkable story of cancer therapy. Recently, the advent of oral arsenic formulations (oral-arsenic trioxide and Realgar-Indigo Naturalis formula (RIF)) based regimens may provide a therapeutic advance by curing APL with two oral agents. Indeed, the oral RIF plus all-trans-retinoic acid (ATRA) without chemotherapy display highly efficacy in patients with APL. The safety profile of RIF plus ATRA make possible to treat APL patients in a home-based manner during postremission therapy. To our knowledge, RIF was the first commercially available oral arsenic agent approved in China. The RIF plus ATRA regimens are becoming a preferred frontline care for APL in China. In this review, we will discuss the history, current evidences and challengers of RIF-based strategies in APL. More and more APL patients may enjoy a cure with a normal quality-of-life after induction in the near future.
摘要
急性早幼粒细胞白血病（APL）的治疗模式绝不是癌症治疗中最引人注目的故事。最近，基于口服砷制剂（口服三氧化二砷和雄黄-靛蓝天然配方（RIF））的治疗方案可能通过使用两种口服药物治愈APL而带来治疗进展。事实上，口服RIF加全反式维甲酸（ATRA）且不进行化疗在APL患者中显示出高度疗效。RIF加ATRA的安全性使得在缓解后治疗期间以居家方式治疗APL患者成为可能。据我们所知，RIF是中国首个获批的商用口服砷剂。RIF加ATRA方案正成为中国APL首选的一线治疗方案。在本综述中，我们将讨论基于RIF的APL治疗策略的历史、当前证据和挑战。在不久的将来，越来越多的APL患者在诱导治疗后可能会以正常的生活质量获得治愈。
相似文献
1
Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia.口服雄黄-青黛配方加维甲酸治疗急性早幼粒细胞白血病。
Front Oncol. 2021 Feb 5;10:597601. doi: 10.3389/fonc.2020.597601. eCollection 2020.
2
Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.口服砷剂联合维甲酸与静脉用砷剂联合维甲酸治疗非高危急性早幼粒细胞白血病的非劣效性、随机、3 期临床试验。
Lancet Oncol. 2018 Jul;19(7):871-879. doi: 10.1016/S1470-2045(18)30295-X. Epub 2018 Jun 5.
3
Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.初诊急性早幼粒细胞白血病患者采用口服砷剂联合维 A 酸方案早期转换门诊治疗模式的疗效和安全性。
Leuk Res. 2019 Aug;83:106168. doi: 10.1016/j.leukres.2019.106168. Epub 2019 Jun 8.
4
5
Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies.口服与静脉用砷剂治疗急性早幼粒细胞白血病的疗效和不良反应：一项随机对照研究的荟萃分析。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820937008. doi: 10.1177/1533033820937008.
6
Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.三氧化二砷与复方青黛胶囊治疗儿童急性早幼粒细胞白血病多中心随机对照研究：SCCLG-APL 临床研究的中期结果。
Am J Hematol. 2018 Dec;93(12):1467-1473. doi: 10.1002/ajh.25271. Epub 2018 Oct 20.
7
Safety and efficacy of Compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia: Clinical evidence and potential mechanisms.复方黄黛片联合全反式维甲酸治疗急性早幼粒细胞白血病的安全性和有效性：临床证据及潜在机制
Chin Herb Med. 2021 Sep 13;14(1):154-165. doi: 10.1016/j.chmed.2021.09.004. eCollection 2022 Jan.
8
The simpler, the better: oral arsenic for acute promyelocytic leukemia.越简单越好：口服砷剂治疗急性早幼粒细胞白血病。
Blood. 2019 Aug 15;134(7):597-605. doi: 10.1182/blood.2019000760. Epub 2019 May 21.
9
Realgar-indigo naturalis formula for the treatment of patients with relapsed and arsenic trioxide-resistant acute promyelocytic leukemia: A case series.雄黄-青黛配方治疗复发及耐三氧化二砷急性早幼粒细胞白血病患者：病例系列研究。
J Integr Med. 2024 Sep;22(5):614-620. doi: 10.1016/j.joim.2024.08.001. Epub 2024 Aug 8.
10
PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.诱导治疗结束时 PML-RARA 转录本水平与一线用全反式维甲酸加砷治疗的非高危急性早幼粒细胞白血病的预后相关：单中心队列研究的长期随访。
Br J Haematol. 2021 Dec;195(5):722-730. doi: 10.1111/bjh.17752. Epub 2021 Aug 17.
引用本文的文献
1
Effects of realgar-indigo naturalis formula on a zebrafish tumor xenograft model induced by human acute promyelocytic leukemia cells: antitumor activity, hepatotoxicity, and transcriptomic analysis.雄黄-青黛方对人急性早幼粒细胞白血病细胞诱导的斑马鱼肿瘤异种移植模型的影响：抗肿瘤活性、肝毒性及转录组分析
Front Pharmacol. 2025 Jul 18;16:1619352. doi: 10.3389/fphar.2025.1619352. eCollection 2025.
2
The Potential Use of Arsenic Trioxide in the Treatment of Systemic Lupus Erythematosus.三氧化二砷治疗红斑狼疮的潜力。
Int J Mol Sci. 2024 Sep 4;25(17):9577. doi: 10.3390/ijms25179577.
3
Natural products as potential drug treatments for acute promyelocytic leukemia.天然产物作为急性早幼粒细胞白血病的潜在药物治疗手段。
Chin Med. 2024 Apr 3;19(1):57. doi: 10.1186/s13020-024-00928-8.
4
Indirubin, an Active Component of Indigo Naturalis, Exhibits Inhibitory Effects on Leukemia Cells Targeting HSP90AA1 and PI3K/Akt Pathway.靛玉红，天然靛蓝的一种活性成分，通过靶向 HSP90AA1 和 PI3K/Akt 通路发挥抑制白血病细胞的作用。
Anticancer Agents Med Chem. 2024;24(9):718-727. doi: 10.2174/0118715206258293231017063340.
5
Vincamine, from an antioxidant and a cerebral vasodilator to its anticancer potential.从抗氧化剂和脑血管扩张剂到其抗癌潜力的 Vincamine。
Bioorg Med Chem. 2023 Sep 7;92:117439. doi: 10.1016/j.bmc.2023.117439. Epub 2023 Aug 9.
6
Comparative pharmacokinetics and urinary excretion of arsenic and mercury after oral administration of realgar, cinnabar and AnGongNiuHuang Pill to rats.大鼠口服雄黄、朱砂及安宫牛黄丸后砷和汞的比较药代动力学及尿排泄情况
Front Pharmacol. 2022 Aug 30;13:967608. doi: 10.3389/fphar.2022.967608. eCollection 2022.
7
Realgar (AsS), a traditional Chinese medicine, induces acute promyelocytic leukemia cell death via the Bcl-2/Bax/Cyt-C/AIF signaling pathway .雄黄（AsS）是一种传统的中药，通过 Bcl-2/Bax/Cyt-C/AIF 信号通路诱导急性早幼粒细胞白血病细胞死亡。
Aging (Albany NY). 2022 Sep 12;14(17):7109-7125. doi: 10.18632/aging.204281.
8
Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome.抑制李-弗劳梅尼综合征中的癌症启动
Cancers (Basel). 2022 Mar 23;14(7):1621. doi: 10.3390/cancers14071621.
9
Study on the Mechanism of Reducing Hepatotoxicity of Water-Grinding Realgar by Metabolomics, Morphology, and Chemical Analysis.基于代谢组学、形态学及化学分析的水飞雄黄减毒机制研究
Evid Based Complement Alternat Med. 2021 Dec 14;2021:8538287. doi: 10.1155/2021/8538287. eCollection 2021.
本文引用的文献
1
PML-RARA monitoring in newly diagnosed acute promyelocytic leukemia treated with an entirely oral chemotherapy-free postremission approach: A multiple institution experience.采用完全口服无化疗缓解后治疗方法的新诊断急性早幼粒细胞白血病中PML-RARA监测：多机构经验
Hematol Oncol. 2020 Oct;38(4):618-621. doi: 10.1002/hon.2766. Epub 2020 Jul 29.
2
Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators.急性早幼粒细胞白血病首次完全缓解后口服三氧化二砷、全反式维甲酸和维生素 C 维持治疗：长期结果和独特的预后指标。
Cancer. 2020 Jul 15;126(14):3244-3254. doi: 10.1002/cncr.32937. Epub 2020 May 4.
3
100-Year-Old Haematologica Images: Acute Promyelocytic Leukemia.百年血液学影像：急性早幼粒细胞白血病
Haematologica. 2020 Jan 31;105(2):245. doi: 10.3324/haematol.2020.247056. Print 2020.
4
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.全反式维甲酸和三氧化二砷治疗非高危急性早幼粒细胞白血病的长期结果：APL0406意大利-德国随机试验的更新
Leukemia. 2020 Mar;34(3):914-918. doi: 10.1038/s41375-019-0589-3. Epub 2019 Oct 14.
5
Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.初诊急性早幼粒细胞白血病患者采用口服砷剂联合维 A 酸方案早期转换门诊治疗模式的疗效和安全性。
Leuk Res. 2019 Aug;83:106168. doi: 10.1016/j.leukres.2019.106168. Epub 2019 Jun 8.
6
The simpler, the better: oral arsenic for acute promyelocytic leukemia.越简单越好：口服砷剂治疗急性早幼粒细胞白血病。
Blood. 2019 Aug 15;134(7):597-605. doi: 10.1182/blood.2019000760. Epub 2019 May 21.
7
Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.三氧化二砷与复方青黛胶囊治疗儿童急性早幼粒细胞白血病多中心随机对照研究：SCCLG-APL 临床研究的中期结果。
Am J Hematol. 2018 Dec;93(12):1467-1473. doi: 10.1002/ajh.25271. Epub 2018 Oct 20.
8
Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.口服砷剂联合维甲酸与静脉用砷剂联合维甲酸治疗非高危急性早幼粒细胞白血病的非劣效性、随机、3 期临床试验。
Lancet Oncol. 2018 Jul;19(7):871-879. doi: 10.1016/S1470-2045(18)30295-X. Epub 2018 Jun 5.
9
Oral arsenic and all- retinoic acid for high-risk acute promyelocytic leukemia.口服砷剂和全反式维甲酸治疗高危急性早幼粒细胞白血病。
Blood. 2018 Jun 28;131(26):2987-2989. doi: 10.1182/blood-2018-02-834051. Epub 2018 May 4.
10
Long-term survival of acute promyelocytic leukaemia patients treated with arsenic and retinoic acid.接受砷剂和维甲酸治疗的急性早幼粒细胞白血病患者的长期生存情况。
Br J Haematol. 2016 Sep;174(5):820-2. doi: 10.1111/bjh.13809. Epub 2015 Nov 13.
Zotero 插件